WuXi XDC, Boostimmune Sign MOU

WuXi XDC, a contract research, development, and manufacturing organization (CRDMO), and Boostimmune, a biotech company focused on developing next-generation anti-cancer therapies, announced on Aug. 11, 2023 that they have signed a memorandum of understanding (MOU) for comprehensive, integrated discovery services for Boostimmune’s pipeline.

Under the collaboration, Boostimmune will have access to WuXi XDC’s bioconjugate platform and drug discovery expertise. WuXi XDC will provide end-to-end services to support Boostimmune’s discovery of novel bioconjugates.

Boostimmune’s pipeline projects consist of naked, monoclonal antibodies to modulate the tumor immune microenvironment; antibody drug conjugates aimed at novel targets with potential patient-selection biomarkers; and an immune stimulator antibody conjugate (ISAC) directly targeting immunosuppressive myeloid cells, according to a company press release.

“Boostimmune is focused on answering urgent unmet clinical needs and dedicated to providing patients around the world with high-quality, innovative therapies,” said Gwanghee Lee, co-founder and CEO of Boostimmune, in the press release. “Accessing WuXi XDC’s … bioconjugate platform and … industry know-how will afford exciting opportunities for us to explore novel ADCs and other bioconjugates that could become transformative therapeutics.”

“Our fully integrated, one-stop platform will accelerate the ADC discovery timeline and enable Boostimmune to advance its innovative pipeline,” said Jimmy Li, CEO of WuXi XDC, in the press release. “As a global CRDMO, we aim to continually enhance our platform and help propel the growth of the bioconjugate industry for the benefit of patients worldwide.”

Source: WuXi Biologics